Stock comparison
ResMed
Teleflex
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$29.57B
Sector
Healthcare
TFX
Teleflex
Market cap
$5.74B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | TFX | Winner |
|---|---|---|---|
| Warren Buffett | 64C | 24F | RMD |
| Benjamin Graham | 67B | 26F | RMD |
| Philip Fisher | 67B | 23F | RMD |
| Peter Lynch | 50C | 1F | RMD |
| Joel Greenblatt | 39D | 27F | RMD |
| Charlie Munger | 61C | 18F | RMD |
| Terry Smith | 65B | 15F | RMD |
Side-by-side metrics
| Metric | RMD | TFX |
|---|---|---|
| Market cap | $29.57B | $5.74B |
| P/E (TTM) | 19.6x | - |
| EV/EBIT | 17.1x | 21.9x |
| ROIC (TTM) | 19.63% | 2.73% |
| Gross margin | 61.69% | 53.27% |
| Net margin | 27.44% | -35.89% |
| Revenue CAGR 5y | 12.64% | -8.23% |
| EPS CAGR 5y | 30.73% | - |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 1.14% | 1.05% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- Net margin27.44%vs -35.89%+176%
- Revenue CAGR 5y12.64%vs -8.23%+165%
- ROIC (TTM)19.63%vs 2.73%+86%
- Market cap$29.57Bvs $5.74B+81%
TFX leads on
- P/E (TTM)-vs 19.6x+129%
- Debt / Equity0.1xvs 0.1x+57%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.